Efficient and accurate prediction of molecular properties, such as lipophilicity and solubility, is highly desirable for rational compound design in chemical and pharmaceutical industries. To this end, we build and apply a graph-neuralnetwork framework called self-attention-based message-passing neural network (SAMPN) to study the relationship between chemical properties and structures in an interpretable way. The main advantages of SAMPN are that it directly uses chemical graphs and breaks the black-box mold of many machine/deep learning methods. Specifically, its attention mechanism indicates the degree to which each atom of the molecule contributes to the property of interest, and these results are easily visualized. Further, SAMPN outperforms random forests and the deep learning framework MPN from Deepchem. In addition, another formulation of SAMPN (Multi-SAMPN) can simultaneously predict multiple chemical properties with higher accuracy and efficiency than other models that predict one specific chemical property. Moreover, SAMPN can generate chemically visible and interpretable results, which can help researchers discover new pharmaceuticals and materials. The source code of the SAMPN prediction pipeline is freely available at Github (https ://githu b.com/tbwxm u/SAMPN ).
The focused drug repurposing of known approved drugs (such as lopinavir/ritonavir) has been reported failed for curing SARS-CoV-2 infected patients. It is urgent to generate new chemical entities against this virus. As a key enzyme in the life-cycle of coronavirus, the 3C-like main protease (3CL pro or M pro ) is the most attractive for antiviral drug design. Based on a recently solved structure (PDB ID: 6LU7), we developed a novel advanced deep Q-learning network with the fragment-based drug design (ADQN-FBDD) for generating potential lead compounds targeting SARS-CoV-2 3CL pro . We obtained a series of derivatives from those lead compounds by our structure-based optimization policy (SBOP). All the 47 lead compounds directly from our AI-model and related derivatives based on SBOP are accessible in our molecular library at https://github.com/tbwxmu/2019-nCov. These compounds can be used as potential candidates for researchers in their development of drugs against SARS-CoV-2.author/funder. All rights reserved. No reuse allowed without permission. : bioRxiv preprint disease (COVID-19) worldwide. 1 As of March 2, 2020, more than 90,000 people have been infected by SARS-CoV-2 and more than 3000 people have been reported dead according to Johns Hopkins Coronavirus map tracker. 2 The numbers of infection and death are still increasing. To face the considerable threat of SARS-CoV-2, it is urgent to develop new inhibitors or drugs against this deadly virus. Unfortunately, since the outbreak of severe acute respiratory syndrome (SARS) eighteen years ago, there has been no approved treatment against the SARS coronavirus (SARS-CoV), 3 which is similar to SARS-CoV-2. Repurposing potential drugs such as lopinavir and ritonavir also failed to SARS-CoV-2 injected patients. 4 Structure-based antiviral drug design with a new artificial intelligence algorithm may represent a more helpful approach to get the SARS-CoV-2 targeted inhibitors or drugs. Thanks to the prompt efforts of many researchers, we have several pieces of important information about this vital virus genome and protein structures. We now know that the non-structural protein 5 (Nsp5) is the main protease (M pro ) of SARS-CoV-2 and it is a cysteine protease, which also been called "3C-like protease" (3CL pro ). Moreover, we know that the 3D structure of 3CL pro is very similar to SARS-CoV with a sequence identity of >96% and 3D structure superposition RMSDCα of 0.44 Å as shown in Figures S1 and S2. 3CL pro has been reported as an attractive target for developing anti-coronaviral drugs: 1) this protease is highly conserved in both sequences and 3D structures; 5 2) 3CL pro is a key enzyme for related virus (including SARS and SARS-CoV-2) replication; 3) it only exists in the virus, not in humans. Developing specific antiviral drugs targeting 3CL pro of the specific virus has shown significant success; for example, both approved drugs lopinavir and ritonavir can completely occupy the substrate-binding site of 3CL pro to break down the replication of human immunodeficien...
A mild and efficient method was developed for the copper-catalyzed additions of H-phosphonate diesters to boronic acids under the copper catalyst system Cu(2)O/1,10-phenanthroline. To the best of our knowledge this finding is the first example of a copper-catalyzed synthesis of aryl phosphonates from arylboronic acids and H-phosphonate dialkyl esters.
A new compound (1), named diaporthelactone, together with two known compounds (2 and 3) were isolated from the culture of Diaporthe sp., a marine fungus growing in the submerged rotten leaves of Kandelia candel in the mangrove nature conservation areas of Fugong, Fujian Province of China. The new compound was elucidated to be 1,3-dihydro-4-methoxy-7-methyl-3-oxo-5-isobenzofuran-carboxyaldehyde (1), which showed cytotoxic activity against KB and Raji cell lines (IC50 6.25 and 5.51 microg mL(-1), respectively). Two known compounds, 7-methoxy-4,6-dimethyl-3H-isobenzofuran-1-one (2) and mycoepoxydiene (3), were also demonstrated to exhibit cytotoxic activities for the first time. All three compounds were assessed for antimicrobial activity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.